Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Axsome Thera
(NQ:
AXSM
)
73.76
+0.07 (+0.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Axsome Thera
< Previous
1
2
3
4
Next >
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022
December 07, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Struggling Axsome Stock Could Bounce Back on Drug Trial Success
November 30, 2022
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.
Via
MarketBeat
Exposures
Product Safety
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
November 28, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 23, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
November 09, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 07, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
October 27, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022
October 21, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
October 20, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
October 10, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
October 03, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
September 29, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME THERAPEUTICS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM
August 26, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
AXSOME THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM
July 30, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
July 28, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
July 12, 2022
From
The Schall Law Firm
Via
Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)
July 11, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
July 11, 2022
From
The Schall Law Firm
Via
Business Wire
AXSOME DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Axsome Therapeutics, Inc. and Encourages Investors to Contact the Firm
July 08, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
NASDAQ:AXSM Investor Notice: Deadline on July 12, 2022 in Lawsuit Against Axsome Therapeutics, Inc.
July 08, 2022
San Diego, CA -- (SBWIRE) -- 07/08/2022 -- The Shareholders Foundation announced that a deadline is coming up on July 12, 2022 in the lawsuit filed for certain investors of Axsome Therapeutics, Inc....
Via
SBWire
ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses Over $100K to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM
July 04, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ROSEN, A LEADING NATIONAL FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM
June 29, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM
June 15, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
June 28, 2022
Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent...
Via
FinancialNewsMedia
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM
June 11, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Small-Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)
June 06, 2022
Via
AB Newswire
Axsome Therapeutics, Inc. Investor News: Robbins LLP is Investigating Axsome Therapeutics, Inc. (AXSM) on Behalf of Shareholders
June 01, 2022
From
Robbins LLP
Via
Business Wire
NATIONALLY RANKED ROSEN LAW FIRM Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM
May 28, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)
May 26, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)
May 24, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.